Hyundai ADM Bio, together with its parent company Hyundai Bioscience, announced on the company's website on October 24 the interim preclinical ...

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

The group partnered with Medac Gesellschaft für klinische Spezialpräparate for the exclusive rights to commercialise the ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

Beta Drugs Limited is the first Indian company to introduce Methotrexate Oral Solution, a patient-friendly alternative to tablets for various medical conditions such as leukemia, lymphomas, and ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a clinical trial, scientists found that a Mediterranean diet could ...

A 16-week Mediterranean diet intervention significantly improved psoriasis severity and metabolic health in adults with mild to moderate psoriasis. The study demonstrated a notable reduction in ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

Tremfya is the first IL-23 inhibitor approved for pediatric plaque psoriasis and psoriatic arthritis, based on the PROTOSTAR trial's positive results. The PROTOSTAR trial demonstrated significant skin ...